跳至主要内容
临床试验/NCT06489860
NCT06489860撤回2 期

SARS-CoV-2 Safety Study for the Treatment of COVID-19

DHA Coffee Co., Ltd1 个研究点 分布在 1 个国家开始时间: 2025年1月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
试验地点
1
主要终点
SARS-CoV-2

研究概览

简要总结

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to protect Telomere chromosomes to maintain Acid Deoxyribonucleic (ADN) Molecules.

详细描述

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to change and disappear defective cells in virus variants, Covid-19 disease. Pluripotent stem cells produced strong cells serve as a repair system, replacing damaged cells, defective cells and dead cells.

CHEMISTRY:

SARS-CoV-2 does not use any chemicals, no colors and no additives and no preservatives.

Toxicology:

SARS-CoV-2 product is not adverse effect, non-toxic and no pharmacal toxicology.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

盲法说明

Directions: For adults and for Children 1-12 years old. Indication: SARS-CoV-2 Ingredient: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved.

Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: <5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date. Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity).

入排标准

年龄范围
1 Year 至 130 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • SARS-CoV-2

排除标准

  • 未提供

研究组 & 干预措施

SARS-CoV-2 Safety Study for the Treatment of COVID-19

Experimental

Directions: For adults and for Children 1-12 years old. Indication:SARS-CoV-2 Ingredients: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved.

Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: <5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date. Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity).

干预措施: HIV (Drug)

SARS-CoV-2 Safety Study for the Treatment of COVID-19

Experimental

Directions: For adults and for Children 1-12 years old. Indication:SARS-CoV-2 Ingredients: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved.

Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: <5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date. Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity).

干预措施: Malignant Neoplasms Safety Study for the Treatment of Neoplasms (Drug)

结局指标

主要结局

SARS-CoV-2

时间窗: From September to October, 2024

1. Parameters: Humidification, Unit: %, Result: 4.40, Test Method: ISO 7932: 2004. 2. Cadmium (Cd), mg/Kg, 0.1, CASE.TN.0018 (Ref. AOAC 999.11). 3. Hydrargyrum (Hg), mg/Kg, 0.01, CASE.TN.0141 (Ref . EPA Method 7473). 4. Plumbum (Pb), mg/liter, 0.001, SMEWW3030E 2017: 31258: 2017. 5. Cadmium (Cd), mg/liter, 0.0001, SMEWW3030E 2017: 31258: 2017. . 6. Arsen (As), mg/liter, 0.001, SMEWW3030E 2017: 31258: 2017. 7. Hydrargyrum (Hg), mg/liter, 0.0001, SMEWW3030E 2017: 31258: 2017. 8. Clostridium perfringents, CFU/g, \< 10, ISO 7937:2004. 9. Coliforms, CFU/g, \< 10, ISO 4832:2006 (\*). 10. Escherichia coli, CFU/g, \< 10, ISO 7937:2006. 11. Salmonella, /25g, Not detected, ISO 7937:2007. 12. Staphylococcus aureus, CFU/g, \< 10, ISO 7937:2008. 13. Total Yeasts molds, CFU/g, \< 10, ISO 7937:2009. 14. Total Aerobic Microbial, CFU/g, 1.0 x 100, ISO 7937:2010. 15. Vibrio parahaemolyticuc, /25g, Not detected, ISO 7937:2011. .

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Principal Investigator
主要研究者

Do Van Tin

DHA Coffee Co., Ltd

DHA Coffee Co., Ltd

研究点 (1)

Loading locations...

相似试验